biote Corp.

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
7.39 ^USD	-0.14%		-1.07%	+49.60%

07-01	Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	CI
07-01	Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index	CI

Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index

July 30, 2024

biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index

Latest news about biote Corp.

Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	06-30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index	06-30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Defensive Index	06-30	CI
Biote Reaches $60 Million Settlement to Repurchase Shares From Stockholder	06-20	MT
Biote Corp. announces an Equity Buyback for 8,300,000 shares, for $60 million.	06-20	CI
Biote Corp. authorizes a Buyback Plan.	06-19	CI
Biote Shares Fall After Report by Short-Seller J Capital	05-20	MT
Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	05-09	CI
Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	05-07	MT
Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024	05-07
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Biote Corp. Reaffirms Earnings Guidance for the Year 2024	05-07	CI
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	04-05	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	04-03	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	03-26	MT
Biote Corp. completed the acquisition of Asteria Health.	03-13	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	03-13	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	03-12	MT
Biote Corp. Provides Revenue Guidance for 2024	03-12	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	02-20	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	02-01	MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	01-26	MT

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company